0001562180-23-003442.txt : 20230405 0001562180-23-003442.hdr.sgml : 20230405 20230405163611 ACCESSION NUMBER: 0001562180-23-003442 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230403 FILED AS OF DATE: 20230405 DATE AS OF CHANGE: 20230405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Smith Mark Douglas CENTRAL INDEX KEY: 0001756253 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38977 FILM NUMBER: 23803093 MAIL ADDRESS: STREET 1: C/O TELADOC HEALTH, INC. STREET 2: 2 MANHATTANVILLE ROAD, SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Phreesia, Inc. CENTRAL INDEX KEY: 0001412408 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 BUSINESS ADDRESS: STREET 1: 1521 CONCORD PIKE STREET 2: SUITE 301 PMB 221 CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: 888-654-7473 MAIL ADDRESS: STREET 1: 1521 CONCORD PIKE STREET 2: SUITE 301 PMB 221 CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Phreesia Inc DATE OF NAME CHANGE: 20070914 4 1 primarydocument.xml PRIMARY DOCUMENT X0407 4 2023-04-03 false 0001412408 Phreesia, Inc. PHR 0001756253 Smith Mark Douglas C/O PHREESIA, INC. 1521 CONCORD PIKE, SUITE 301 PMB 221 WILMINGTON DE 19803 true false false false true Common Stock 2023-04-03 4 M false 7000.00 4.71 A 23112.00 D Common Stock 2023-04-03 4 S false 6500.00 30.6895 D 16612.00 D Common Stock 2023-04-03 4 S false 500.00 31.771 D 16112.00 D Stock Option 4.71 2023-04-03 4 M false 7000.00 0.00 D 2028-09-04 Common Stock 7000.00 65193.00 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 18, 2023. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.33 to $31.19 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $31.93 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 27,306 of the original 84,193 shares underlying the option vested became exercisable on September 5, 2019, with 25% of the remainder vesting on September 5, 2019, and 75% of the remainder vesting in thirty-six (36) equal monthly installments thereafter. /s/ Alexis Lyons, as Attorney-in-Fact for Smith Mark Douglas 2023-04-05